ASH 2018 | AML highlights from ASH 2018

Guillermo Garcia-Manero

Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, delivers key highlights, including exciting trials, future outlooks, and developments in the field of acute myeloid leukemia (AML) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video  
Similar topics
Related videos
2:11
An exciting era for CAR T-cell therapy
Mohamad Mohty
2:11
Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill
2:11
Ibrutinib combinations for CLL: iLLUMINATE results & more
Carol Moreno
2:11
JCAR017 for relapsed/refractory CLL
Tanya Siddiqi
2:11
Combining novel agents for CLL to achieve deep remissions: time-limited therapy, treatment cessation & drug re-use in relapse
Talha Munir
Acute Myeloid Leukemia, Leukemia
Antibodies, Checkpoint Inhibitors, Pracinostat, Venetoclax
ASH 2018
Interview
More from Guillermo Garcia-Manero
Updates from ASH 2018 in MDS therapy
Promising results in MDS for ASTX727, an oral decitabine and cytidine deaminase inhibitor agent
Pracinostat for AML update: follow-up analysis and Phase III trial
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals